WBB Securities reported on Cidara Therapeutics (NASDAQ:CDTX), upping its price target to $10.50 earlier today
- Updated: September 22, 2016
WBB Securities raised the target price of Cidara Therapeutics (NASDAQ:CDTX) to $10.50 stating a possible downside of -0.14%.
Boasting a price of $12.27, Cidara Therapeutics (NASDAQ:CDTX) traded -1.87% lower on the day. The last stock close price is up 3.32% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $11.61 and a 200-day average of $11.65. Trade Volume was down over the average, with 11,094 shares of CDTX changing hands under the typical 54,133
See Chart Below
With a total market value of $0, Cidara Therapeutics has one year low of $9.48 and a one year high of $18.07 .
General Company Details For Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.